
Ariad names Manmeet Soni CFO
pharmafile | March 14, 2016 | Appointment | Business Services, Sales and Marketing | Ariad, CEO, appointment, boardroom, cfo
Ariad Pharmaceuticals Inc (Nasdaq: ARIA) named Manmeet Soni chief financial officer, effective March 21, 2016, succeeding Edward Fitzgerald.
Mr Soni will report to the Chief Executive Paris Panayiotopoulos.
CEO Paris Panayiotopoulos, said: “I am delighted that Manmeet will be joining Ariad as our chief financial officer. Manmeet brings to Ariad proven finance and transaction expertise and will play a critical role in completing our strategic review to further strengthen our position as a leading orphan oncology company.”
Most recently Mr Soni served as chief financial officer of biopharmaceutical company Pharmacyclics Inc. Previously, Mr Soni worked at Zeltiq Aesthetics Inc as the controller and senior director of finance.
Mr Soni, said: “I am very pleased about this opportunity to join the talented and passionate team at Ariad, a company focused on making a difference in the lives of cancer patients with breakthrough medicines. I look forward to working with Paris and the rest of the team in developing and executing on Ariad’s corporate strategy, while concentrating on building long-term value for shareholders.”
In December the Ariad named Paris Panayiotopoulos as president and chief executive, effective January 1, 2016.
Anjali Shukla
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






